210 related articles for article (PubMed ID: 23290982)
21. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
22. Zoledronic acid induced unilateral anterior uveitis.
Gupta S; Onkar A; Vashisht T
Indian J Ophthalmol; 2020 Sep; 68(9):2002-2003. PubMed ID: 32823458
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonate-associated orbital inflammation--a case report and review.
Peterson JD; Bedrossian EH
Orbit; 2012 Apr; 31(2):119-23. PubMed ID: 22489855
[TBL] [Abstract][Full Text] [Related]
24. Treatment of acute anterior uveitis in the community, as seen in an emergency eye centre. A lesson for the general practitioner?
Mercieca K; Jones NP
Eur J Gen Pract; 2012 Mar; 18(1):26-9. PubMed ID: 21936761
[TBL] [Abstract][Full Text] [Related]
25. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
Anastasilakis AD; Polyzos SA; Makras P; Sakellariou GT; Bisbinas I; Gkiomisi A; Delaroudis S; Gerou S; Ballaouri I; Oikonomou D; Papapoulos SE
Bone; 2012 May; 50(5):1130-4. PubMed ID: 22366634
[TBL] [Abstract][Full Text] [Related]
26. Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women.
Lafage-Proust MH
Kidney Int; 2008 Sep; 74(5):557-9. PubMed ID: 18709026
[TBL] [Abstract][Full Text] [Related]
27. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
Boonen S; Sellmeyer DE; Lippuner K; Orlov-Morozov A; Abrams K; Mesenbrink P; Eriksen EF; Miller PD
Kidney Int; 2008 Sep; 74(5):641-8. PubMed ID: 18509324
[TBL] [Abstract][Full Text] [Related]
28. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
[TBL] [Abstract][Full Text] [Related]
29. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.
Billington EO; Horne A; Gamble GD; Maslowski K; House M; Reid IR
Osteoporos Int; 2017 Jun; 28(6):1867-1874. PubMed ID: 28233020
[TBL] [Abstract][Full Text] [Related]
30. A single infusion of zoledronate prevents bone loss after stroke.
Poole KE; Loveridge N; Rose CM; Warburton EA; Reeve J
Stroke; 2007 May; 38(5):1519-25. PubMed ID: 17395868
[TBL] [Abstract][Full Text] [Related]
31. What do we know about the ocular adverse effects associated with intravenous bisphosphonates?
Atik OS
Eklem Hastalik Cerrahisi; 2011; 22(1):1. PubMed ID: 21417978
[No Abstract] [Full Text] [Related]
32. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
[TBL] [Abstract][Full Text] [Related]
33. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
Ding Y; Zeng JC; Yin F; Zhang CL; Zhang Y; Li SX; Liu X; Zhang C; Xue QY; Lin H; Pei FX
Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
[TBL] [Abstract][Full Text] [Related]
34. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
Huang J; Meixner L; Fernandez S; McCutchan JA
AIDS; 2009 Jan; 23(1):51-7. PubMed ID: 19050386
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonate-associated orbital inflammatory disease and uveitis anterior--a case report and review.
Böni C; Kordic H; Chaloupka K
Klin Monbl Augenheilkd; 2013 Apr; 230(4):367-9. PubMed ID: 23629782
[TBL] [Abstract][Full Text] [Related]
36. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
37. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).
Chapman I; Greville H; Ebeling PR; King SJ; Kotsimbos T; Nugent P; Player R; Topliss DJ; Warner J; Wilson JW
Clin Endocrinol (Oxf); 2009 Jun; 70(6):838-46. PubMed ID: 18823395
[TBL] [Abstract][Full Text] [Related]
38. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
Boonen S; Orwoll E; Magaziner J; Colón-Emeric CS; Adachi JD; Bucci-Rechtweg C; Haentjens P; Kaufman JM; Rizzoli R; Vanderschueren D; Claessens F; Sermon A; Witvrouw R; Milisen K; Su G; Lyles KW;
J Am Geriatr Soc; 2011 Nov; 59(11):2084-90. PubMed ID: 22091563
[TBL] [Abstract][Full Text] [Related]
39. Characterization of and risk factors for the acute-phase response after zoledronic acid.
Reid IR; Gamble GD; Mesenbrink P; Lakatos P; Black DM
J Clin Endocrinol Metab; 2010 Sep; 95(9):4380-7. PubMed ID: 20554708
[TBL] [Abstract][Full Text] [Related]
40. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
